Germ Cell Tumours V
Springer London Ltd (Verlag)
978-1-85233-563-2 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
The Fifth International Germ Cell Tumour Conference brings together clinicians and scientists and covers all aspects of the disease from basic tumour biology, genetics and pathology through to clinical management. This edition should be a useful reference to the proceedings for those involved in treating the disease. As well as including information on optimum treatment and trial results, this book provides a forum for the interaction of scientists and clinicians addressing relevant issues. In the search for the optimum trial design in the 21st century, the book begins with data on DNA repair and malignant cell adaptation to resist conventional therapies, moving to potential strategies to overcome that resistance. It should have most value for clinical specialists and researchers who treat testicular, ovarian or extragonadal germ cell tumours.
Section 1 Genetics and Biology 1. The genetics of testicular germ cell tumours 2. Advances in the understanding of germ cell tumour biology 3. A Notch-related gene located on the long arm of human chromosome 12 4. Investigating gain of 12p material in testicular germ cell tumours and its apparent absence in intratubular germ cell neoplasia. 5. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of testicular seminomas and non-seminomas. 6. Reactivity of germ cell maturation stage-specific markers in classical and spermatocytic Seminoma. 7. Expression of human endogenous retroviruses HERV-K/HTDV in germ cell tumours: possible biological role and clinical application. 8. No association between HLA Class II genes and testicular germ tumour (TGCT) with genotyping of the HLA-Region on chromosome 6p21 and haplotype sharing analysis. 9. RT-PCR for AFP, HCG, GCAP and PDGF-1 to detect circulating tumour cells in testicular germ cell tumours. 10. The prognostic significance of tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance. 11. HIV related testicular cancer. 12. Microinvasive testicular germ cell tumours: prevalence in stage I tumours. 13. Serum lactate dehydrogenase isoenzyme 1 in patients with testicular seminoma or nonseminoma stage I: two nationwide Danish studies of surveillance. 14. The atrophy hypothesis and development of malignant germ cell cancers of the testis. Section 2 Why do treatments fail? Implications for clinical trial strategy 15. Prognosis and Prognostic Factors. 16. Role of the human apurinic endonuclease Ape1/ref-1 in germ cell tumours. 17. Translational implications of Ape1 in germ cell tumours: Ape1 as a therapeutic target. 18. Current clinical trials in germ cell tumours in the United States 19. Topoisomerase I and II in germ cell cancer as indicators of possible drug selection for salvage chemotherapy studies Section 3 Non-testicular germ cell tumours 20. Overview of female germ cell tumours. 21. Germ cell tumours of the ovary: A clinicopathological study of 121 cases from Nepal. 22. Serum lactate dehydrogenase isoenzyme 1 in patients with testicular and ovarian germ cell tumours. Section 4 Paediatric germ cell tumours 23. Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free and survival rates for children and adolescents with gonadal malignant germ cell tumours (MGCT): A POG/CCG Intergroup Report. 24. Treatment strategy for childhood extracranial secreting germ cell tumours based on alphafoetoprotein (AFP) level: protocol TGM95 of the Societe Francaise d'Oncologie Pediatrique (SFOP). 25. Risk factors in malignant extracranial germ cell tumours (MGCTs) of childhood: analysis of UKCCSG's GCII study. 26. A watch and-wait-strategy is a safe procedure in children and adolescents with malignant non-testicular germ cell tumours (GCTs): Results of the German Consecutive MAKEI 83/86/89 and 96 protocols. 27. Mediastinal germ cell tumours (MGCT) in children and adolescents: age correlates with histological differentiation, genetic profiles and clinical outcome. 28. Intracranial Malignant Germ Cell Tumours (CNS GCTs): Interim Results of the SIOP Trial. 29. Treatment of primary intracranial germ cell tumours with in-based chemotherapy and focal irradiation. rns of relapse following focal irradiation of intracranial : critical review of TGM-TC90 SFOP protocol. t of Residual Lesions in Intracranial Germinoma- Interim SIOP CNS GCT 96 Study. re of treatment in childhood extracranial and icular germ cell tumours (MGCT). 5 Current status - surgery ry for germ cell tumours: current status in the USA. ry for testicular cancer: UK and European experience tion of residual masses: a decade of research with Jan ctive factors for residual teratoma after
| Erscheint lt. Verlag | 24.4.2002 |
|---|---|
| Zusatzinfo | 44 figures, references, index |
| Verlagsort | England |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Gynäkologie / Geburtshilfe |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie | |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| ISBN-10 | 1-85233-563-7 / 1852335637 |
| ISBN-13 | 978-1-85233-563-2 / 9781852335632 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
